Home / Inspections / 1055912

FDA Inspection 1055912 — Aurolife Pharma, LLC

Aurolife Pharma, LLC — FEI 3005796917

The FDA completed an inspection of Aurolife Pharma, LLC on June 14, 2018 in Dayton, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
June 14, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Dayton, NJ (United States)

Facility

Other inspections at this facility

  • 1158258 (OAI Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1109452 (VAI Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 980107 (NAI Thu Jul 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 952634 (NAI Tue Jan 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 933659 (NAI Thu Jul 09 2015 00:00:00 GMT+0000 (Coordinated Universal Time))

Recent compliance actions

FDA data resources